VIVUS Inc. (VVUS) will report its next earnings on May 1 – May 5 ... analysis for VIVUS Inc. and for the current quarter 2 analysts have projected that the stock could give an Average Earnings estimate of $-0.14/share. These analysts have …
Following U.S. election volatility some analysts have updated their recommended target prices on shares of VIVUS, Inc. (NASDAQ:VVUS). According to the most recently released broker notes, 0 analysts have a rating of “strong buy” on …
Late Tuesday, VIVUS, Inc. (Nasdaq: VVUS) announced FDA approval for its weight-management drug Qsymia. Shares have resumed trading markedly higher ahead of the bell Wednesday, amid the recent run-up in the stock. Importantly, …
If you want a Stock Review on VRTX, VVUS, XBIT or AXON then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. Biotechnology is a highly volatile and unpredictable sector due to the …
To read the entire report visit: www.microstockprofit.com/lp/VVUS See what investors are saying about VVUS at penny stock forum MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com …
This SHOULD have been a $30-$300 dollar stock. Oh. And they have installed an management team fully on board with the program. Naturally." 6 months ago web/kev said VVUS would be $60.00 a share by the end of the year.I will put my …
Shares of biotech company VIVUS (Nasdaq: VVUS) have been on a roller-coaster ride lately as a result of contrasting headlines in the news. The stock plummeted last month when patent concerns surfaced surrounding the company's …
Within three days, shares of VVUS were closing above their 5-day moving average, rallying into strength on the final trading day of the week. In closing above its 5-day moving average on Friday, the stock had gains 3-4% for traders who bought …
Vivus (VVUS)'s stock rose on news that a phase 3 study showed its new erectile dysfunction drug, avanafil, produced "erections sufficient for intercourse" 80 percent of the time. So far, so good. But the devil is in the details with this drug. …